Aurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunction

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- #AdvancingScience--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced the completion of patient enrollment in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration investigational regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has the potential to